Brief: European Commission Approves Pfizer’S Hympavzi For The Treatment Of Adults And Adolescents With Hemophilia A Or B With Inhibitors
13/05/2026 11:46
May 13 (Reuters) - Pfizer Inc PFE.N: EUROPEAN COMMISSION APPROVES PFIZER’S HYMPAVZI FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH HEMOPHILIA A OR B WITH INHIBITORS PFIZER : EUROPEAN COMMISSION APPROVES HYMPAVZI EXPANSION FOR HEMOPHILIA A/B PATIENTS AGES 12+ WITH INHIBITORS PFIZER - HYMPAVZI MARKETING AUTHORIZATION VALID IN ALL 27 EU STATES, ICELAND, LIECHTENSTEIN, AND NORWAY Source text: ID:nBw76jpM2a Further company coverage: PFE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials